Please try another search
For the six months ended 30 June 2018, United BioPharma Inc revenues increased from NT$5K to NT$6.8M. Net loss increased 40% to NT$341.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development Expenses - Bala increase of 58% to NT$201.4M (expense), General and Administrative Expenses - Ba increase of 80% to NT$49.3M (expense).
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 6.8 | 0 | 0.01 | 28.81 |
Gross Profit | 5.04 | -2.7 | -0.21 | 20.89 |
Operating Income | -341.12 | -319.27 | -250.69 | -185 |
Net Income | -341.91 | -322.8 | -244.67 | -177.1 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 3753.73 | 3682.59 | 3422.24 | 3283.64 |
Total Liabilities | 1194.37 | 784.55 | 1094.26 | 718.18 |
Total Equity | 2559.36 | 2898.04 | 2327.98 | 2565.46 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -173.47 | -329.96 | -158.36 | -281.46 |
Cash From Investing Activities | -146.84 | -691.55 | -349.81 | -740.02 |
Cash From Financing Activities | 403.64 | 1158.13 | 254.32 | 800 |
Net Change in Cash | 82.5 | 136.2 | -253.85 | -221.48 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review